Anzeige
Mehr »
Sonntag, 05.10.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 854607 | ISIN: JP3814000000 | Ticker-Symbol: FJI
Tradegate
03.10.25 | 12:12
21,300 Euro
+1,38 % +0,290
Branche
Konsumgüter
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
FUJIFILM HOLDINGS CORPORATION Chart 1 Jahr
5-Tage-Chart
FUJIFILM HOLDINGS CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
20,93021,32004.10.
20,82021,24003.10.
GlobeNewswire (Europe)
381 Leser
Artikel bewerten:
(2)

FUJIFILM Europe GmbH: Medical Inventor Celebrates 20 Years of Double Balloon Enteroscopy in Europe with New Endoscope Launch

INTRODUCING THE NEW ERA OF DBE

RATINGEN, Germany, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Developed in collaboration with renowned medical device inventor Professor Hironori Yamamoto, Fujifilm Healthcare is excited to announce the launch of the new EN-840T DBE Endoscope in Europe on October 12, 2024.

WORKING WITH THE INVENTOR OF DBE

Inventor Professor Hironori Yamamoto is the Chairman and Professor of the Department of Medicine, Division of Gastroenterology, at Jichi Medical University in Tochigi, Japan.

Fujifilm's collaboration with Prof. Yamamoto, the inventor of Double Balloon Endoscopy, has presented a unique opportunity to develop a range of endoscopes that support healthcare professionals in addressing challenges within the endoscopy procedure using new technologies.

GOLD STANDARD FOR SAFE EXPLORATION OF THE BOWEL

"Double-balloon endoscopy is safe and effective for the diagnosis and treatment of small-bowel disorders."1

Used in 80 countries worldwide, DBE is the gold standard for safe exploration of the bowel. That's why Fujifilm Healthcare Europe is leading the way with its specialist DBE products, delivering imaging precision and enhanced usability for endoscopy professionals.

IMAGING CLARITY FOR ENDOSCOPY
"DBE is less invasive and more convenient for the patient than intraoperative small-bowel endoscopy." 2

DBE endoscopes are more convenient2 to use than surgical alternatives and cost-effective2 for healthcare providers. With a continued focus on patient safety, imaging accuracy and reduced procedure time within its endoscopy product range, the Fujifilm DBE EN-840T Endoscope provides clarity and convenience for healthcare professionals with its new high-resolution CMOS Sensor.

PATIENT SAFETY AND SIMPLICITY

"An endoscopy is part of a patient's diagnostic or therapeutic journey…the quality and safety of endoscopy depends on the environment within which endoscopists work (including the facilities and equipment)..." 3

Fujifilm is committed to continually supporting endoscopy healthcare professionals in providing safe care for their patients with Fujifilm's best equipment. With a simple set-up process, the EN-840T endoscope is easy to use, allowing effortless operation and manoeuvrability during procedures.

Now Available!
The New EN-840T Double Balloon Endoscope is available in Europe since 12th October 2024.

Learn More

Read the Brochure to discover more: Download Brochure

View the Fujifilm EN-840T setup guide: https://youtu.be/2redrjTDpPA

Fujifilm, Proudly by Your Side
Recently celebrating 90 years as a global innovator in healthcare and imaging, Fujifilm's innovative med-tech solutions are designed to transform healthcare services for patients, delivering a continued positive impact on society. With our knowledge, passion and inspiration, we empower Healthcare Professionals to make the biggest difference in their daily work, byimprovingthe quality of life for patients. Together, we are enriching lives and giving the world more smiles!

Contact Us
Want to learn more about this product or have a question for our team?

Contact us here: endoscopy_eu@fujifilm.com

Stefan Bachmeier
Fujifilm Healthcare Europe
stefan.bachmeier@fujifilm.com

_______________

1Yamamoto et al., Dig. Endosc. 2015; 27: 331-337. Doi: 10.1111/den.12378; https://pubmed.ncbi.nlm.nih.gov/25180488/
2 Rahmi G et al., 2017; Efficacy of double-balloon enteroscopy for small-bowel polypectomy: clinical and economic evaluation. Efficacy of double-balloon enteroscopy for small-bowel polypectomy: clinical and economic evaluation - PMC3Valori, Cortas, Rutter et al. 2019; Performance measures for endoscopy services: A European Society of Gastrointestinal Endoscopy

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/09ce25aa-0187-4c19-8e66-f0e05aa73ddc


© 2024 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.